The theory of homogeny of liver and kidney in the treatment of kidney and liver fibrosis

<正>Chronic kidney disease(CKD) and chronic liver disease are both very harmful to human health almost all over the world,which lead to the fibrosis of the two organs ultimately.Currently,there are few satisfactory therapeutic methods in treating the two diseases.Some research works from Chinese medicine and Western medicine were done in the area recently,the results showed that kidney and liver fibrosis shared similar biological signals and events such as epithelialmesenchymal transition(EMT) and transforming growth factorβ1,the same herbal medicine exhibited significantly improving effects on both liver fibrosis and kidney fibrosis by involving similar mechanism.This coincides with the theory of homogeny of Liver(Gan) and Kidney(Shen) of Chinese medicine.It would provides new clues in exploring the treatment of liver fibrosis and kidney fibrosis.     

由肝肾相关理论探讨高血压病

高血压病是最常见的心血管疾病,当属中医的"眩晕""头痛""中风"等范畴,发病与肝肾有密切关系。中医对高血压病的认识多由肝肾相关理论进行阐述,该文具体从肝肾的病理改变以及肝肾阴阳失调对高血压病的病因病机进行探讨,为临床治疗高血压病提供理论依据。     

从“肝肾同源”论探讨骨质疏松症病因病机及其治疗原则

从中医基础理论和现代医学的病因病机两个方面,论述"肝肾同源"理论与骨质疏松症之间发生、发展过程中的相关性。认为骨质疏松症与"肝肾同源"学说紧密相关。骨质疏松症病位在骨,涉及多个脏腑,主要与肝肾脾相关。其病因复杂,主要病机是肾精亏虚、肝气郁结、脾气亏虚。根据肝郁肾虚脾虚病机,其治疗原则宜补肾柔肝健脾。文章为"肝肾同源"理论预防和治疗骨质疏松症提供理论依据。     

糖肾方改善糖脂代谢紊乱“肝肾同治”机制研究

糖脂代谢紊乱造成的肝肾损伤严重危害国民健康,目前临床仍缺乏有效防治药物。糖肾方是在 “益气柔肝、活血通络”思想指导下建立的中药复方。多中心临床试验证明,糖肾方能够显著降低糖尿病肾病尿 蛋白的排泄,提高肾小球率过滤,其疗效优于目前西医治疗糖尿病肾病一线用药ACEI/ARB。同时,糖肾方能 够有效改善模型动物脂代谢紊乱及肝肾脂质沉积,保护肝肾功能。进一步研究发现糖肾方通过调控mTOR、 NF-kB、TGF-β/Smad等信号通路,发挥肝肾保护和治疗作用。本研究将临床试验、动物模型、细胞实验和先进 的分子生物学技术相结合,系统研究糖肾方纠正糖脂代谢通路紊乱所致肝肾损伤机制,阐释了糖肾方“肝肾同 治”的物质和理论基础,丰富了祖国医学“肝肾同源”的理论内涵。     

肝硬化后肾损害的研究现状和临床科研思路探析

以中医学“肝肾同源论”为基础,提出在发病学上肝肾具有共同的致病途径,在研究肝硬化相关肾纤维化时,要注重脏器纤维化的关联性。在治疗学上倡导“肝病治肾”、“肝肾同活”。进而认识到多脏器纤维化之间的相互作用,并认为肝肾在脏器纤维化发生机制上具有相关性,中药肾疏宁具有清热利湿解毒、活血化瘀、补益脾肾作用,肾疏宁及中药单体可能通过干预Smad7蛋白表达、TGF—β1等细胞因子而发挥抗纤维化作用,为中药治疗肝硬化后肾损害的机制提供了研究思路。